Maria Elvira Purchases Biogen Inc. Shares

Maria Elvira disclosed buying Biogen Inc. shares valued between $1,001 and $15,000.

Written by Opentrades · Published Jun 12, 2026, 9:21 PM EDT · Updated Jun 13, 2026, 2:10 AM EDT

Key Points

Maria Elvira, a member of the House, bought Biogen shares valued between $1,001 and $15,000 on May 11, 2026.
Biogen Inc. trades near $199.96 with a market cap of approximately $29.5 billion and a P/E ratio of 21.5.
Analysts from Needham and RBC Capital have recently given Biogen a 'buy' rating with price targets of $255 and $227 respectively.

Congressional trading track record

Maria Elvira vs. the S&P 500

YTD return +15.5% hypothetical

All-time return -4.3% S&P 500 +57.2%

vs. S&P 500 -61.5% behind the index

Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.

Maria Elvira, a member of the U.S. House of Representatives, recently disclosed a purchase of Biogen Inc. shares valued between $1,001 and $15,000. The transaction was reported on June 9, 2026, but took place on May 11, 2026. Biogen, trading on the NasdaqGS under the ticker BIIB, is a major player in the healthcare sector.

Biogen Inc. Stock Snapshot

Shares of NasdaqGS:BIIB are currently trading near $199.96. Biogen Inc. has a market capitalization of approximately $29.5 billion. The company maintains a price-to-earnings (P/E) ratio of 21.5 and a forward P/E ratio of 12.0. It has a beta of 0.177, indicating lower volatility compared to the market. The stock's 52-week range spans from $121.05 to $205.97, with a 50-day moving average of $188.47 and a 200-day moving average of $173.14.

Other Institutional Activity in Biogen Inc.

Institutional investors have been actively trading Biogen shares. BlackRock, Inc. increased its holdings by 1,163,231 shares, ending with 15,974,601 shares valued at about $2.93 billion. FMR LLC significantly boosted its position by 3,381,678 shares, holding a total of 12,807,541 shares worth approximately $2.35 billion. Meanwhile, State Street Corp made a minor addition of 8,902 shares, bringing its total to 7,167,922 shares valued at $1.31 billion.

Recent Earnings

Biogen reported revenue of $9.94 billion, reflecting a growth of 1.9%. The company's net margin stands at 13.8%, and it has a return on equity (ROE) of 7.7%. Biogen is expected to announce its next earnings results on April 29, 2026.

Insider Buying and Selling at Biogen Inc.

Several insiders have been buying shares of Biogen. On June 9, 2026, Menelas Pangalos purchased 2,370 shares, while Eric Rowinsky and Stephen Sherwin each acquired 1,505 shares. Maria Freire bought 2,005 shares on the same day. These transactions were not part of a pre-arranged trading plan.

Analysts Set New Price Targets

On June 8, 2026, Needham upgraded Biogen to a 'buy' rating, setting a price target of $255. RBC Capital maintained its 'buy' rating with a target of $227 on May 27, 2026. Piper Sandler reiterated a 'buy' rating with a $225 target on May 15, 2026. The consensus among 30 analysts is a 'buy' with an average target price of $220.63.

About Biogen Inc.

Biogen Inc., headquartered in Cambridge, Massachusetts, is a leading biotechnology company. It focuses on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is known for its treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, among others. Biogen operates globally, with a workforce of approximately 7,500 employees.

Bottom Line

Maria Elvira's purchase of Biogen shares highlights ongoing interest in this major biotech firm. As a leader in neurological therapies, Biogen continues to attract attention from both institutional investors and analysts. While this disclosure is based on past transactions, it provides insight into the company's appeal in the market.